China's ADC drug market is expected to reach 68.9 billion yuan in 2030In recent years, antibody-conjugated drugs (ADCs) have attracted much attention from the global pharmaceutical industry as an important breakthrough in the field of tumor treatment. Driven by policy support, capital investment and

New Element Pharmaceutical submits an application for listing on the Hong Kong Stock Exchange: Innovative pharmaceutical companies accelerate capitalization processRecently, the pharmaceutical industry has welcomed another major news. According to the Hong Kong Stock Exchange, Xin Element Pharmaceut

The application for the launch of the new HER2 dual anti-KN026 drug by Shiyao Group and Corning Jerry has been accepted by NMPA for HER2-positive gastric cancer.Recently, Shijiao Group and Corning Jerry Biopharma jointly announced that the application (NDA) for the new drug marketing application (ND

A total of 22 rare disease drugs were approved worldwide in August, involving 19 rare diseases.In recent years, the research and development and approval of rare disease drugs have been significantly accelerated, bringing more hope for treatment for patients with rare diseases around the world. In A

Wearable devices, telemedicine and other technologies promote the development of health management servicesIn recent years, with the rapid development of technology, wearable devices and telemedicine technology have gradually become hot topics in the field of health management. These technologies no

Haizheng Pharmaceutical and Aixindawei reach exclusive licensing and strategic cooperation on the world's first small molecule prodrug AST-3424Recently, Haizheng Pharmaceutical and Shenzhen Aixindawei Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Aixindawei") announced an exclusiv

Hypertensive vaccine HJY-ATRQ-001 has been accepted as a national first-class biological innovative drug.Recently, the National Drug Administration (NMPA) officially accepted the clinical trial application for the hypertension vaccine HJY-ATRQ-001, marking an important step in my country's treatment

Fragile X syndrome (FXS) small molecule oral medication transactions reach $450 millionRecently, the pharmaceutical industry ushered in a major deal, with a biopharmaceutical company reaching a global exclusive license agreement for small molecule oral medications for Fragile X Syndrome (FXS) for US

Ionis Pharmaceuticals candidate ION582 has been recognized as a breakthrough therapy for the treatment of angel syndromeRecently, Ionis Pharmaceuticals announced that its drug candidate ION582 has been awarded the Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for th

"Duchenne Muscular Dystrophy Multidisciplinary Management Guide (2025 Edition)" ReleaseRecently, the International Association for Neuromuscular Diseases (INMD) and experts from many countries around the world jointly released the "Guidelines for the Management of Multidisciplinary Duchenne Muscular